Drugs / HYNR-CS inj
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01363401 | Feb 2011 → May 2013 | amyotrophic lateral sclerosis | Corestemchemon, Inc. | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HYNR-CS inj | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01363401 ↗ |
| Known as | HYNR-CS | “After the clinical trial (phase I/II) was conducted, the stem cell (HYNR-CS, NEURONATA-R) was included in the revision of the regulations on orphan drug designation” PMID 25934946 ↗ May 2015 |
| Known as | NEURONATA-R | “After the clinical trial (phase I/II) was conducted, the stem cell (HYNR-CS, NEURONATA-R) was included in the revision of the regulations on orphan drug designation” PMID 25934946 ↗ May 2015 |
| Route | Intrathecal | “through intrathecal delivery” NCT01363401 ↗ |